Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.58) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.10, Briefing.com reports. The business had revenue of $25.60 million for the quarter, compared to analyst estimates of $12.55 million. Kymera Therapeutics had a negative return on equity of 31.92% and a negative net margin of 194.67%. The company’s revenue was up 55.2% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.67) EPS.
Kymera Therapeutics Price Performance
Shares of Kymera Therapeutics stock traded down $0.57 during trading on Friday, hitting $41.44. The stock had a trading volume of 296,304 shares, compared to its average volume of 668,746. The firm has a market cap of $2.54 billion, a P/E ratio of -16.51 and a beta of 2.22. The business has a fifty day moving average of $37.09 and a two-hundred day moving average of $37.05. Kymera Therapeutics has a fifty-two week low of $9.60 and a fifty-two week high of $48.70.
Insider Activity
In other news, Director Joanna Horobin sold 8,500 shares of the company’s stock in a transaction on Friday, June 7th. The stock was sold at an average price of $32.99, for a total transaction of $280,415.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, Director Bruce Booth sold 16,740 shares of the stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $35.45, for a total value of $593,433.00. Following the completion of the sale, the director now directly owns 803,792 shares of the company’s stock, valued at approximately $28,494,426.40. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Joanna Horobin sold 8,500 shares of the stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $32.99, for a total value of $280,415.00. The disclosure for this sale can be found here. Insiders sold a total of 502,345 shares of company stock valued at $19,279,932 over the last three months. Insiders own 15.82% of the company’s stock.
Wall Street Analyst Weigh In
Read Our Latest Stock Report on KYMR
About Kymera Therapeutics
Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
Featured Stories
- Five stocks we like better than Kymera Therapeutics
- What Does Downgrade Mean in Investing?
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- How to Buy Cheap Stocks Step by Step
- MarketBeat Week in Review – 8/5 – 8/9
- Investing in Commodities: What Are They? How to Invest in Them
- The Cannabis Sector: Profitability Takes Center Stage
Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.